Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0002094682-25-000003
Filing Date
2025-12-05
Accepted
2025-12-05 15:20:20
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 33556
2 LETTER TO BOD TCRTletterconformed.pdf EX-20 205112
  Complete submission text file 0002094682-25-000003.txt   317994
Mailing Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301
Business Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301 (346) 355-4099
Alaunos Therapeutics, Inc. (Subject) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-79364 | Film No.: 251552663
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 6 THE PENINSULA PANORAMA ROAD POOLE United Kingdom BH13 7RS
Business Address
Price Adrian (Filed by) CIK: 0002094682 (see all company filings)

Type: SCHEDULE 13D/A